StemGen benefits from a 15 year experience of its researchers in the field of brain stem cell biology and employs proprietary cell culture technologies and know-how for the identification and optimisation of novel glioblastoma therapeutics.
StemGen routinely establishes stable cell lines from human brain cancers, that represent a previously unavailable tool to perform high throughput, predictive drug-screening for anti-cancer molecules. This system is amenable for a highly reproducible investigation of chemical, genetic, and protein libraries on a very large scale. Using these technologies, StemGen has identified and patented a series of leading compounds that specifically target tumour-initiating cells within human tumours. Alone or in combination with traditional therapies, these can both inhibit cancer growth and also avoid tumor recurrence.
StemGen is in the process of applying for clinical trial investigation in the glioblastoma area and is actively expanding in this area of research, identifying new active molecules, and also studying the cellular and molecular mechanism of action of its leading compounds, to expand its portfolio of effective therapeutic products.